The FDA has approved the supplemental New Drug Application sNDA for Cinvanti (aprepitant) to expand administration to include a 2-minute intravenous injection, in addition to the already approved 30-minute IV infusion.
First-trimester ondansetron use is associated with a small increased risk for oral cleft but no increased risk for congenital malformations or cardiac malformations, according to a new study.
The prefilled syringe is part of the Company’s Simplist portfolio and is the first FDA-approved prefilled delivery version of palonosetron hydrochloride (HCI) to become available.
The prevalence of prenatal marijuana use was 5.3% by self-report or toxicologic test findings; prevalence was greater among females with severe and mild versus no NVP (11.3 and 8.4, respectively, vs 4.5%).
The recall affects approximately 470,000 units that include drugs packaged with 3 to 10 tablets per blister card. The blister packs were developed for use in hospitals, however some were sent to retail pharmacies and were likely dispensed for in-home use.
For the same 25 cases, a Heat Index screening threshold of 85 degrees Fahrenheit could identify potentially hazardous levels of workplace environmental heat when WBGT was unavailable. Six fatalities occurred when the Heat Index was <91 degrees Fahrenheit.
The Warnings and Precautions section for both products has been updated to inform clinicians that there have been reports of false positive urine screening tests for methadone, opiates, and phencyclidine phosphate (PCP) with doxylamine succinate/pyridoxine hydrochloride use.
The latest Consensus Guidelines for the Management of PONV (CGM-PONV) recommend an assessment of a patient’s baseline risk for PONV using a validated risk score based on independent predictors.
The intravenous formulation combines fosnetupitant (prodrug of netupitant), a substance P/NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist.
Akynzeo IV combines fosnetupitant (prodrug of netupitant), a substance P/NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist.
